|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CCDC107 |
Gene summary for CCDC107 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CCDC107 | Gene ID | 203260 |
| Gene name | coiled-coil domain containing 107 | |
| Gene Alias | PSEC0222 | |
| Cytomap | 9p13.3 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q8WV48 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 203260 | CCDC107 | S016 | Human | Liver | HCC | 2.46e-14 | 8.73e-01 | 0.2243 |
| 203260 | CCDC107 | S027 | Human | Liver | HCC | 4.22e-11 | 1.29e+00 | 0.2446 |
| 203260 | CCDC107 | S028 | Human | Liver | HCC | 1.95e-22 | 1.27e+00 | 0.2503 |
| 203260 | CCDC107 | S029 | Human | Liver | HCC | 3.27e-25 | 1.81e+00 | 0.2581 |
| 203260 | CCDC107 | C04 | Human | Oral cavity | OSCC | 1.31e-08 | 9.23e-01 | 0.2633 |
| 203260 | CCDC107 | C21 | Human | Oral cavity | OSCC | 1.91e-17 | 8.04e-01 | 0.2678 |
| 203260 | CCDC107 | C30 | Human | Oral cavity | OSCC | 1.58e-20 | 1.19e+00 | 0.3055 |
| 203260 | CCDC107 | C43 | Human | Oral cavity | OSCC | 1.77e-23 | 4.79e-01 | 0.1704 |
| 203260 | CCDC107 | C46 | Human | Oral cavity | OSCC | 2.48e-07 | -4.68e-03 | 0.1673 |
| 203260 | CCDC107 | C51 | Human | Oral cavity | OSCC | 5.42e-07 | 6.86e-01 | 0.2674 |
| 203260 | CCDC107 | C57 | Human | Oral cavity | OSCC | 1.87e-02 | 1.78e-01 | 0.1679 |
| 203260 | CCDC107 | C06 | Human | Oral cavity | OSCC | 4.26e-08 | 1.35e+00 | 0.2699 |
| 203260 | CCDC107 | C08 | Human | Oral cavity | OSCC | 3.13e-09 | 1.36e-01 | 0.1919 |
| 203260 | CCDC107 | LN46 | Human | Oral cavity | OSCC | 7.89e-06 | -4.73e-02 | 0.1666 |
| 203260 | CCDC107 | EOLP-1 | Human | Oral cavity | EOLP | 2.03e-02 | -1.72e-02 | -0.0202 |
| 203260 | CCDC107 | NEOLP-2 | Human | Oral cavity | NEOLP | 1.69e-06 | 1.39e-01 | -0.0196 |
| 203260 | CCDC107 | NEOLP-3 | Human | Oral cavity | NEOLP | 2.16e-05 | 1.23e-01 | -0.0191 |
| 203260 | CCDC107 | SYSMH1 | Human | Oral cavity | OSCC | 2.76e-03 | -3.32e-02 | 0.1127 |
| 203260 | CCDC107 | SYSMH3 | Human | Oral cavity | OSCC | 9.30e-08 | 5.12e-01 | 0.2442 |
| 203260 | CCDC107 | SYSMH4 | Human | Oral cavity | OSCC | 5.29e-13 | -2.91e-01 | 0.1226 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CCDC107 | insertion | Frame_Shift_Ins | novel | c.562_563insGTGATTGGGTTTTT | p.Lys188SerfsTer14 | p.K188Sfs*14 | Q8WV48 | protein_coding | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| CCDC107 | SNV | Missense_Mutation | novel | c.155C>A | p.Pro52Gln | p.P52Q | Q8WV48 | protein_coding | tolerated(0.11) | possibly_damaging(0.667) | TCGA-C5-A3HD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
| CCDC107 | SNV | Missense_Mutation | c.221N>T | p.Ala74Val | p.A74V | Q8WV48 | protein_coding | tolerated(0.11) | possibly_damaging(0.741) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| CCDC107 | SNV | Missense_Mutation | rs762343169 | c.533N>T | p.Ser178Leu | p.S178L | Q8WV48 | protein_coding | tolerated_low_confidence(0.15) | benign(0) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| CCDC107 | SNV | Missense_Mutation | novel | c.647N>G | p.Asp216Gly | p.D216G | Q8WV48 | protein_coding | deleterious(0.01) | benign(0.23) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| CCDC107 | SNV | Missense_Mutation | c.363N>T | p.Glu121Asp | p.E121D | Q8WV48 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CCDC107 | SNV | Missense_Mutation | c.777N>C | p.Lys259Asn | p.K259N | Q8WV48 | protein_coding | tolerated_low_confidence(0.1) | benign(0.007) | TCGA-AP-A054-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | PD | |
| CCDC107 | SNV | Missense_Mutation | novel | c.559N>A | p.Asp187Asn | p.D187N | Q8WV48 | protein_coding | tolerated_low_confidence(0.43) | benign(0.011) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CCDC107 | SNV | Missense_Mutation | novel | c.467N>C | p.Ile156Thr | p.I156T | Q8WV48 | protein_coding | deleterious(0) | possibly_damaging(0.814) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| CCDC107 | SNV | Missense_Mutation | rs202093963 | c.472G>A | p.Glu158Lys | p.E158K | Q8WV48 | protein_coding | tolerated(0.07) | benign(0.015) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |